Prenatal diagnosis of homozygous alpha-thalassemia-1 by cell-free fetal DNA in maternal plasma

• Main Authors: Sirichotiyakul,S., Charoenkwan,P., Sanguansermsri,T.
• Format: Article
• Published: John Wiley and Sons Ltd 2015
• Subjects: Obstetrics and Gynecology; Genetics (clinical)
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84857502562&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38195
• Institution: Chiang Mai University

Objective: To investigate the use of cell-free fetal DNA (cff-DNA) to determine fetal status in pregnant women who were risk for having Hb Bart's. Methods: Plasma DNA was extracted from 10mL of maternal blood from couples who both were alpha-thalassemia-1 carriers (SEA deletion). Real time quantitative PCR was performed using fluorescence-labeled probes to monitor wild type (wt) and SEA allele. The quantity of each allele was determined by cycle threshold (Ct). ΔCt (Ct of wt- Ct of SEA) was calculated from each sample. Prenatal diagnosis was performed to determine fetal status. Result: There were 62 Hb Bart's, 62 alpha-trait and 34 normal fetuses in this study. Mean ΔCt was 1.04±0.38, 0.21±0.37 and 0.14±0.55 in Hb Bart's, alpha-trait and normal fetuses, respectively. Based on ROC, the best cut-off of ΔCt for predicting Hb Bart's was 0.51, giving 98.4% sensitivity and 20.8% false-positive rate. All but one Hb Bart's (98.4%) had ΔCt above 0.51, whereas 74.2% of alpha-trait and 88.2% of normal fetuses had ΔCt below 0.51. Conclusion: There is a positive trend to use cff-DNA in maternal plasma for prenatal diagnosis of homozygous alpha-thalassemia-1. With this technique, invasive prenatal testing and complications can be avoided in 79.2% of unaffected fetuses. © 2011 John Wiley & Sons, Ltd..